
Immunic CMO discusses significance of MS Awareness Month; progress with treatment
0:00
11:08
Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the company’s work in multiple sclerosis (MS) as MS Awareness Month concludes. Muehler discussed the importance of continued research funding and the community’s role in advancing treatment.
He highlighted the company’s lead asset, vidofludimus calcium, which is in advanced-stage clinical trials. Results from the phase 2 EMPHASIS trial in relapsing-remitting MS showed a reduction of about three-quarters of new MRI lesions compared to placebo. Muehler said, “This is a very good value,” and pointed to biomarker data showing a strong, dose-linear suppression of neurofilament — a sign of nerve cell damage.
A phase 3 program involving more than 2,000 patients is now underway, with data expected in 2026. In progressive MS, Immunic is close to reporting data from its phase 2 CALLIPER trial, having already seen positive biomarker signals at 24 weeks.
Muehler addressed patients’ fears of disability, stressing the company’s commitment to tackling "progression independent of relapse activity (PIRA)", a key unmet need. He emphasized vidofludimus calcium’s dual mechanism — both anti-inflammatory and neuroprotective — and its potential to become the first oral drug targeting the full spectrum of MS.
To hear more insights from Immunic and other biotech leaders, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content.
#ImmunicTherapeutics #MultipleSclerosis #MSAwarenessMonth #vidofludimuscalcium #MSTreatment #ClinicalTrials #Neuroprotection #MSResearch #BiotechNews #ProgressiveMS #RelapsingMS #PIRA #DrugDevelopment
Flere episoder fra "Proactive - Interviews for investors"
Gå ikke glip af nogen episoder af “Proactive - Interviews for investors” - abonnér på podcasten med gratisapp GetPodcast.